Ticker: KYMR

Snapshot - Kymera Therapeutics, Inc. (NASDAQ: KYMR) What's happening inside: Kymera closed a large follow‑on equity raise in June 2025 (initial close $250.8M; underwriters later exercised options bringing total primary proceeds to ~$288.4M) and announced a $40M option/licensing upfront from Gilea...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), is currently focused on developing targeted protein degradation therapies, with several clinical programs underway, including IRAK4 and STAT6. Here's an overview of their recent financial performance and operational highlights. Income Statement Highlights...